N/A
Completed N=130
Understanding Pine Bark Extract as an Alternative Treatment (UPBEAT) Study
Source: ClinicalTrials.gov NCT00425945 ↗Enrolled (actual)
130
Serious AEs
2.3%
Results posted
Apr 2014
Primary outcomePrimary: Combined Change in Systolic and Diastolic Blood Pressures From Baseline to Week 12. — -1.0; -1.9 mm Hg
Summary
The purpose of this study is to investigate the efficacy of Flavangenol® (Toyo Shinyaku, Japan), a pine bark extract, in lowering blood pressure and improving glycemic control and plasma lipoprotein profile.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Combined Change in Systolic and Diastolic Blood Pressures From Baseline to Week 12. |
-1.0; -1.9 | — |
| SECONDARY Total Cholesterol |
5.4; -2.0 | — |
| SECONDARY LDL |
3.3; -1.1 | — |
| SECONDARY HDL |
-0.9; -1.3 | — |
| SECONDARY Triglycerides |
17.2; -1.0 | — |
| SECONDARY LDL Particle Size |
31.4; 28.5 | — |
| SECONDARY HDL Particle Size |
1.0; 0.0 | — |
| SECONDARY Lipoprotein A |
-1.3; 1.8 | — |
| SECONDARY C-reactive Protein |
-0.2; 0.3 | — |
| SECONDARY Body Mass Index |
0.1; -0.1 | — |
| SECONDARY Weight |
0.6; -0.6 | — |
| SECONDARY Fasting Blood Glucose |
-1.0; 0.1 | — |
| SECONDARY Fasting Insulin |
0.2; -0.6 | — |
| SECONDARY Hemoglobin A1c |
-0.0; -0.0 | — |
| SECONDARY ALT/SGPT |
0.8; -3.0 | — |
| SECONDARY AST/SGOT |
0.2; 1.4 | — |
Eligibility Criteria
Inclusion Criteria
- Systolic blood pressure between 125 and 159 mmHg and diastolic blood pressure (DBP) 95 mmHg
- LDL > 170 mg/dL
- TG > 300 mg/dL
- FBG > 110 mg/dL
Data sourced from ClinicalTrials.gov (NCT00425945). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.